These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

777 related items for PubMed ID: 21383284

  • 1. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
    Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P.
    J Clin Oncol; 2011 Apr 01; 29(10):1261-70. PubMed ID: 21383284
    [Abstract] [Full Text] [Related]

  • 2. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.
    Gastroenterology; 2015 Jan 01; 148(1):88-99. PubMed ID: 25305506
    [Abstract] [Full Text] [Related]

  • 3. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY.
    World J Gastroenterol; 2015 Feb 07; 21(5):1595-605. PubMed ID: 25663779
    [Abstract] [Full Text] [Related]

  • 4. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P.
    J Clin Oncol; 2009 Dec 10; 27(35):5931-7. PubMed ID: 19884549
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.
    JAMA Oncol; 2017 Apr 01; 3(4):472-480. PubMed ID: 28006055
    [Abstract] [Full Text] [Related]

  • 7. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.
    J Natl Cancer Inst; 2011 Jun 08; 103(11):863-75. PubMed ID: 21597022
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, Vrettou E, Sgouros J, Samantas E, Basdanis G, Papakostas P, Bafaloukos D, Kotoula V, Kalofonos HP, Scopa CD, Pentheroudakis G, Fountzilas G.
    BMC Cancer; 2015 May 10; 15():384. PubMed ID: 25956750
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K, Ciuleanu TE, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner E, Zielinski CC, Streubel B, Brodowicz T.
    Clin Colorectal Cancer; 2015 Jun 10; 14(2):91-8. PubMed ID: 25666295
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T.
    J Clin Oncol; 2012 May 20; 30(15):1755-62. PubMed ID: 22473155
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
    Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, Oechsle K, Steyerberg E, Hartmann JT, Dinjens WN, Oosterhuis JW, Bokemeyer C, Looijenga LH.
    J Clin Oncol; 2009 May 01; 27(13):2129-36. PubMed ID: 19289622
    [Abstract] [Full Text] [Related]

  • 16. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K, Pongpaibul A, Limwongse C, Roothumnong E, Klaisuban W, Nimmannit A, Jinawath A, Akewanlop C.
    World J Gastroenterol; 2015 Jan 21; 21(3):926-34. PubMed ID: 25624727
    [Abstract] [Full Text] [Related]

  • 17. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.
    Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology.
    J Natl Cancer Inst; 2014 Jul 21; 106(7):. PubMed ID: 24925349
    [Abstract] [Full Text] [Related]

  • 18. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N.
    BMC Cancer; 2015 May 01; 15():340. PubMed ID: 25929517
    [Abstract] [Full Text] [Related]

  • 19. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F.
    J Clin Oncol; 2011 May 20; 29(15):2011-9. PubMed ID: 21502544
    [Abstract] [Full Text] [Related]

  • 20. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA.
    J Natl Cancer Inst; 2017 May 20; 109(5):. PubMed ID: 28040692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.